Literature DB >> 2553963

Histogenesis of cervical adenocarcinoma with reference to human papillomavirus-18 as a carcinogen.

T Okagaki1, T Tase, L B Twiggs, L F Carson.   

Abstract

Human papillomavirus (HPV) DNA is present in adenocarcinoma of the cervix as frequently as in squamous cell carcinoma of the cervix. Recent molecular biologic studies strongly suggested that HPV acts at least as a cocarcinogen in the female genital organs. Thus, a study of the presence of HPV DNA in adenocarcinoma in situ, endocervical glandular dysplasia and microglandular endocervical hyperplasia, three lesions suggested as possible precursor lesions of adenocarcinoma of the cervix, would clarify some aspects of the histogenesis of adenocarcinoma of the cervix. The presence of HPV-6, HPV-16 and HPV-18 in those precursor lesions was studied with highly sensitive in situ DNA hybridization. Fourteen of 21 cases of adenocarcinoma in situ (67%) contained HPV DNA; approximately the same proportion of HPV DNA was seen in invasive adenocarcinoma. Two of 36 cases of endocervical glandular dysplasia contained HPV DNA; both of them were lesions coexisting with adenocarcinoma in situ and thus might have been well-differentiated lesions of adenocarcinoma in situ. HPV DNA was not present in 16 cases of microglandular endocervical hyperplasia. Adenocarcinoma in situ may be the earliest event in HPV infection of the endocervical cells to lead to the development of adenocarcinoma of the cervix.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553963

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  5 in total

Review 1.  Genotypic mapping of HPV and assessment of EBV prevalence in endocervical lesions.

Authors:  J J O'Leary; R J Landers; M Crowley; I Healy; W F Kealy; J Hogan; C Cullinane; P Kelehan; C T Doyle
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

2.  Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma.

Authors:  M Lehtinen; A Leminen; J Paavonen; P Lehtovirta; H Hyöty; E Vesterinen; J Dillner
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

3.  Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma.

Authors:  K Cooper; C S Herrington; E S Lo; M F Evans; J O McGee
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

Review 4.  Testing for human papillomavirus: basic pathobiology of infection, methodologies, and implications for clinical use.

Authors:  D C Wilbur; M H Stoler
Journal:  Yale J Biol Med       Date:  1991 Mar-Apr

5.  Human papillomavirus genotypes distribution in cervical cancer cases in Gabon.

Authors:  Samira Zoa-Assoumou; Angelique Ndjoyi-Mbiguino; Barthelemy Mabika Mabika; Ernest Belembaogo; Abdelkim Khattabi; My Mustapha Ennaji
Journal:  Infect Agent Cancer       Date:  2016-08-16       Impact factor: 2.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.